EP2896703A3 - Mutations of the PIK3CA gene in human cancers - Google Patents

Mutations of the PIK3CA gene in human cancers Download PDF

Info

Publication number
EP2896703A3
EP2896703A3 EP15150891.8A EP15150891A EP2896703A3 EP 2896703 A3 EP2896703 A3 EP 2896703A3 EP 15150891 A EP15150891 A EP 15150891A EP 2896703 A3 EP2896703 A3 EP 2896703A3
Authority
EP
European Patent Office
Prior art keywords
cancers
mutations
pik3ca
human cancers
pi3ks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15150891.8A
Other languages
German (de)
French (fr)
Other versions
EP2896703B1 (en
EP2896703A2 (en
Inventor
Yardena Samuels
Victor Velculescu
Kenneth W. Kinzler
Bert Vogelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2896703(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK17197306.8T priority Critical patent/DK3296407T3/en
Priority to EP17197306.8A priority patent/EP3296407B1/en
Priority to PL17197306T priority patent/PL3296407T3/en
Priority to EP19175606.3A priority patent/EP3556866B1/en
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP2896703A2 publication Critical patent/EP2896703A2/en
Publication of EP2896703A3 publication Critical patent/EP2896703A3/en
Publication of EP2896703B1 publication Critical patent/EP2896703B1/en
Application granted granted Critical
Priority to CY20191100895T priority patent/CY1121975T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the P13K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the colon and other organs. The majority of mutations clustered near two positions within the P13K helical or kinase domains. PIK3CA represents one of the most highly mutated oncogenes yet identified in human cancers and is useful as a diagnostic and therapeutic target.
EP15150891.8A 2004-03-02 2005-02-18 Mutations of the PIK3CA gene in human cancers Active EP2896703B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DK17197306.8T DK3296407T3 (en) 2004-03-02 2005-02-18 Mutations in the PIK3CA gene in human cancers
EP17197306.8A EP3296407B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
PL17197306T PL3296407T3 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
EP19175606.3A EP3556866B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
CY20191100895T CY1121975T1 (en) 2004-03-02 2019-08-21 PIK3CA GENE MUTATIONS IN HUMAN CANCER

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54888604P 2004-03-02 2004-03-02
EP05723277.9A EP1730303B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
EP12164819.0A EP2497836B1 (en) 2004-03-02 2005-02-18 Mutations of the PIK3CA gene in human cancers

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP12164819.0A Division EP2497836B1 (en) 2004-03-02 2005-02-18 Mutations of the PIK3CA gene in human cancers
EP05723277.9A Division EP1730303B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP19175606.3A Division EP3556866B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
EP17197306.8A Division EP3296407B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers

Publications (3)

Publication Number Publication Date
EP2896703A2 EP2896703A2 (en) 2015-07-22
EP2896703A3 true EP2896703A3 (en) 2015-10-21
EP2896703B1 EP2896703B1 (en) 2017-10-25

Family

ID=35056655

Family Applications (5)

Application Number Title Priority Date Filing Date
EP12164819.0A Active EP2497836B1 (en) 2004-03-02 2005-02-18 Mutations of the PIK3CA gene in human cancers
EP15150891.8A Active EP2896703B1 (en) 2004-03-02 2005-02-18 Mutations of the PIK3CA gene in human cancers
EP05723277.9A Active EP1730303B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
EP17197306.8A Active EP3296407B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
EP19175606.3A Active EP3556866B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12164819.0A Active EP2497836B1 (en) 2004-03-02 2005-02-18 Mutations of the PIK3CA gene in human cancers

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP05723277.9A Active EP1730303B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
EP17197306.8A Active EP3296407B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
EP19175606.3A Active EP3556866B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers

Country Status (14)

Country Link
US (6) US8026053B2 (en)
EP (5) EP2497836B1 (en)
JP (10) JP2007530017A (en)
AU (2) AU2005227148B2 (en)
CA (1) CA2560696C (en)
CY (1) CY1121975T1 (en)
DK (3) DK3556866T3 (en)
ES (5) ES2743125T3 (en)
HU (1) HUE045690T2 (en)
LT (1) LT3296407T (en)
PL (2) PL1730303T3 (en)
PT (3) PT3556866T (en)
SI (2) SI3296407T1 (en)
WO (1) WO2005091849A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3296407T (en) 2004-03-02 2019-09-10 The Johns Hopkins University Mutations of the pik3ca gene in human cancers
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
EA201070670A1 (en) * 2007-12-03 2010-12-30 Сантарис Фарма А/С ANTAGONIST RNA COMPOUNDS FOR MODULATION OF PIK3CA EXPRESSION
WO2009152346A2 (en) * 2008-06-11 2009-12-17 Intradigm Corporation Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
CN101445832B (en) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 PIK3CA gene mutation detection probe, detection liquid phase chip and detection method thereof
US20110236916A1 (en) * 2010-03-26 2011-09-29 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
AU2011329180A1 (en) * 2010-11-15 2013-05-02 Enzon Pharmaceuticals, Inc. Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides
US20130317037A1 (en) * 2010-11-16 2013-11-28 Glaxosmithkline Intellectual Property Development Limited Method of administration and treatment
WO2012106175A1 (en) 2011-02-02 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
CN106619647A (en) 2011-02-23 2017-05-10 因特利凯有限责任公司 Combination of mtor inhibitors and pi3-kinase inhibitors and uses thereof
EP3907299A1 (en) 2011-04-15 2021-11-10 The Johns Hopkins University Safe sequencing system
BR112014002121A2 (en) * 2011-07-28 2017-02-21 Genentech Inc pik3ca h1047r non-human knock-in animal breast cancer model
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN102816839A (en) * 2012-07-06 2012-12-12 杭州艾迪康医学检验中心有限公司 Kit for detecting hot spot mutation sites in colorectal cancer PIK3CA gene
EP2912468B1 (en) 2012-10-29 2018-09-12 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
WO2014140061A2 (en) * 2013-03-13 2014-09-18 Roche Diagnostics Gmbh Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene
ES2712798T3 (en) 2013-03-14 2019-05-14 Exact Sciences Dev Co Llc Detection of neoplasms
KR101501826B1 (en) * 2013-04-05 2015-03-13 연세대학교 산학협력단 Method for preparing prognosis prediction model of gastric cancer
EP3027654B1 (en) * 2013-07-30 2019-09-25 Blueprint Medicines Corporation Pik3c2g fusions
EP4234722A3 (en) 2014-03-31 2023-09-20 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
PL3198026T3 (en) 2014-08-07 2020-05-18 Pharmassist Ltd Method of determining pik3ca mutational status in a sample
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CN104531854B (en) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 Kit for detecting drug resistance of cetuximab used for metastatic colorectal cancer treatment by
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
BR112017025254A2 (en) * 2015-05-27 2018-08-07 Quest Diagnostics Investments Incorporated Methods for detecting at least one mutation in a plurality of cancer-related genes, selecting an individual for treatment and predicting the likelihood of responsiveness to treatment.
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
KR20180081042A (en) 2015-08-31 2018-07-13 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 A method for detecting gastric neoplasia
CA3006419A1 (en) 2015-12-03 2017-06-08 Novartis Ag Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
RU2608960C1 (en) * 2016-03-18 2017-01-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Cell line crov cel of human mucinous ovarian carcinoma intended for development of treating with target preparations
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
CN116024334A (en) 2016-04-14 2023-04-28 梅约医学教育与研究基金会 Application of detection DMR reagent in screening IPMN-HGD, panIN-3 or PDAC and kit
US10934592B2 (en) 2017-02-28 2021-03-02 Mayo Foundation For Medical Education And Research Detecting prostate cancer
EP3604521A4 (en) * 2017-03-30 2021-05-19 The University of Tokyo Method for evaluating multiple different genes of interest
JP7067896B2 (en) 2017-10-27 2022-05-16 シスメックス株式会社 Quality evaluation methods, quality evaluation equipment, programs, and recording media
WO2019108626A1 (en) 2017-11-30 2019-06-06 Mayo Foundation For Medical Education And Research Detecting breast cancer
CN111363827A (en) * 2020-04-30 2020-07-03 北京和合医学诊断技术股份有限公司 Primer group for detecting PIK3CA gene mutation and application method thereof
DE102021126650A1 (en) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts METHOD OF DETERMINING THE PROBABILITY OF RESPONSE OF A MALIGNANT DISEASE TO TREATMENT WITH A PHARMACEUTICAL INHIBITING AGENT
CN116219015A (en) * 2023-02-06 2023-06-06 中日友好医院(中日友好临床医学研究所) PCR-based detection kit and detection method for PIK3CA gene mutation in DNA

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
WO1998031324A2 (en) * 1997-01-16 1998-07-23 The Regents Of The University Of California Genetic alterations associated with cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5846824A (en) * 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846624A (en) * 1996-12-06 1998-12-08 The Standard Register Company Dual face pressure sensitive label
US6277563B1 (en) 1997-01-16 2001-08-21 The Regents Of The University Of California Genetic alterations associated with cancer
US6558903B1 (en) 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
EP1144609B1 (en) * 1999-08-27 2008-03-05 Novartis Vaccines and Diagnostics, Inc. Chimeric antisense oligonucleotides and cell transfecting formulations thereof
CA2392438A1 (en) * 2000-01-31 2001-08-02 Craig A. Rosen Nucleic acids, proteins, and antibodies
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20020142305A1 (en) 2001-03-27 2002-10-03 Koei Chin Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers
US20030135033A1 (en) * 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
JP2005533604A (en) 2002-07-25 2005-11-10 アバンテック バスキュラー コーポレーション Apparatus for delivering therapeutic agents and methods related thereto
EA012240B1 (en) * 2003-04-03 2009-08-28 Семафор Фармасьютикалз, Инк. Pi-3 kinase inhibitor prodrugs
LT3296407T (en) 2004-03-02 2019-09-10 The Johns Hopkins University Mutations of the pik3ca gene in human cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
WO1998031324A2 (en) * 1997-01-16 1998-07-23 The Regents Of The University Of California Genetic alterations associated with cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DAO S ET AL: "ANTISENSE INHIBITION OF PIK3CA REVERSES CANCER PHENOTYPE", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 43, 1 March 2002 (2002-03-01), pages 602, XP001206958, ISSN: 0197-016X *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; June 2003 (2003-06-01), LU YILING ET AL: "Targeting PI3K-AKT pathway for cancer therapy.", XP002739618, Database accession no. NLM14763163 *
FRANK CZAUDERNA ET AL: "Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 31, no. 2, 1 January 2003 (2003-01-01), pages 670 - 682, XP002992229, ISSN: 0305-1048, DOI: 10.1093/NAR/GKG141 *
HABECK M: "Knocking down the PI3 kinase pathway", TARGETS, ELSEVIER, vol. 2, no. 2, 1 April 2003 (2003-04-01), pages 38 - 39, XP004886640, ISSN: 1477-3627, DOI: 10.1016/S1477-3627(03)02295-5 *
LIMIN HU ET AL: "Inhibition of Phosphatidylinositol 3?-Kinase Increases Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models", CANCER RESEARCH MOLECULAR ONCOLOGY, M.D. ANDERSON CANCER CENTER, 15 February 2002 (2002-02-15), pages 1087 - 1092, XP055188774, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/62/4/1087.full.pdf> [retrieved on 20150512] *
REVIEWS IN CLINICAL AND EXPERIMENTAL HEMATOLOGY JUN 2003, vol. 7, no. 2, June 2003 (2003-06-01), pages 205 - 228, ISSN: 1127-0020 *
STEIN R C ET AL: "PI3-kinase inhibition: a target for drug development?", MOLECULAR MEDICINE TODAY, ELSEVIER, CAMBRIDGE, GB, vol. 6, no. 9, 1 September 2000 (2000-09-01), pages 347 - 357, XP002351307, ISSN: 1357-4310, DOI: 10.1016/S1357-4310(00)01770-6 *
STEPHEN WARD ET AL: "Therapeutic Potential of Phosphoinositide 3-Kinase Inhibitors", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 10, no. 3, 1 March 2003 (2003-03-01), pages 207 - 213, XP002289830, ISSN: 1074-5521, DOI: 10.1016/S1074-5521(03)00048-6 *

Also Published As

Publication number Publication date
EP2497836A1 (en) 2012-09-12
JP2020115891A (en) 2020-08-06
US20150079593A1 (en) 2015-03-19
JP2013226141A (en) 2013-11-07
EP1730303A4 (en) 2009-09-09
JP2012183065A (en) 2012-09-27
US10422006B2 (en) 2019-09-24
ES2869167T3 (en) 2021-10-25
US10704105B2 (en) 2020-07-07
JP2022059046A (en) 2022-04-12
JP2007530017A (en) 2007-11-01
DK3556866T3 (en) 2021-05-03
JP2018023400A (en) 2018-02-15
EP2896703B1 (en) 2017-10-25
ES2437590T3 (en) 2014-01-13
PL3296407T3 (en) 2019-11-29
US8026053B2 (en) 2011-09-27
JP2016041078A (en) 2016-03-31
JP2020092711A (en) 2020-06-18
ES2869167T8 (en) 2022-01-20
EP1730303B1 (en) 2013-07-31
PT1730303E (en) 2013-10-31
JP6250017B2 (en) 2017-12-20
US20200024671A1 (en) 2020-01-23
DK3296407T3 (en) 2019-08-19
JP7169315B2 (en) 2022-11-10
EP2497836B1 (en) 2015-01-14
CA2560696A1 (en) 2005-10-06
US10787713B2 (en) 2020-09-29
SI1730303T1 (en) 2013-12-31
ES2743125T3 (en) 2020-02-18
AU2005227148A1 (en) 2005-10-06
ES2663248T3 (en) 2018-04-11
LT3296407T (en) 2019-09-10
EP3556866B1 (en) 2021-04-07
CA2560696C (en) 2019-06-25
US11549150B2 (en) 2023-01-10
US20180119231A1 (en) 2018-05-03
EP3556866A1 (en) 2019-10-23
JP7001735B2 (en) 2022-02-10
AU2005227148B2 (en) 2010-11-11
PL1730303T3 (en) 2014-04-30
AU2011200600B2 (en) 2012-02-23
US20200248275A1 (en) 2020-08-06
JP2020028300A (en) 2020-02-27
EP3296407A1 (en) 2018-03-21
ES2537633T3 (en) 2015-06-10
JP5336620B2 (en) 2013-11-06
EP3296407B1 (en) 2019-05-22
WO2005091849A2 (en) 2005-10-06
DK1730303T3 (en) 2013-11-04
WO2005091849A3 (en) 2009-04-16
US20090208505A1 (en) 2009-08-20
CY1121975T1 (en) 2020-10-14
PT3556866T (en) 2021-04-30
JP2018153189A (en) 2018-10-04
JP6694543B2 (en) 2020-05-13
US20110319477A1 (en) 2011-12-29
JP7304987B2 (en) 2023-07-07
PT3296407T (en) 2019-08-23
JP6695381B2 (en) 2020-05-20
JP5894110B2 (en) 2016-03-23
EP2896703A2 (en) 2015-07-22
EP1730303A2 (en) 2006-12-13
JP6395917B2 (en) 2018-09-26
HUE045690T2 (en) 2020-01-28
SI3296407T1 (en) 2019-09-30
AU2011200600A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
EP2896703A3 (en) Mutations of the PIK3CA gene in human cancers
HK1203568A1 (en) Gene expression profiling in biopsied tumor tissues
EP2527360A3 (en) Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2249155A3 (en) Cancer markers
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
EP2386859A3 (en) Diagnostic tumor markers
MX2009003562A (en) Elisa for vegf.
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2006044330A3 (en) Anticancer compounds and methods
WO2007067813A3 (en) Methods and compositions for assessing alterations in gene expression patterns in clinically normal tissues obtained from heterozygous carriers of mutant genes associated with cancer and methods of use thereof
EP2420509A3 (en) Novel marker genes for regulatory T cells from human blood
WO2008099280A3 (en) Regulation of expression of pi3kb protein in tumors
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
WO2012003493A3 (en) Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use
WO2007038073A3 (en) Mutations and polymorphisms of hdac11
WO2007058992A3 (en) Mutations and polymorphisms of hdac6
WO2007030454A3 (en) Mutations and polymorphisms of hdac9
CN205494277U (en) Novel bed is diagnose to intracardiac branch of academic or vocational study
WO2007109183A3 (en) Mutations and polymorphisms of fms-related tyrosine kinase 1
WO2007002217A3 (en) Mutations and polymorphisms of bcl-2
CY1114559T1 (en) PIK3CA GENE TRANSFERS IN HUMAN CANCER
WO2007121017A3 (en) Mutations and polymorphisms of fms-like tyrosine kinase 4
WO2007109515A3 (en) Mutations and polymorphisms of knockdown resistance polypeptide
WO2008033782A8 (en) Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
WO2007053502A3 (en) Mutations and polymorphisms of hdac5

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150113

AC Divisional application: reference to earlier application

Ref document number: 2497836

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1730303

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101AFI20150911BHEP

17P Request for examination filed

Effective date: 20160421

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20160829

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170523

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 1730303

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2497836

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 940002

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005052961

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 940002

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171025

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2663248

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180225

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180125

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180126

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005052961

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

26N No opposition filed

Effective date: 20180726

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180218

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230226

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230223

Year of fee payment: 19

Ref country code: ES

Payment date: 20230301

Year of fee payment: 19

Ref country code: CH

Payment date: 20230307

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230221

Year of fee payment: 19

Ref country code: GB

Payment date: 20230227

Year of fee payment: 19

Ref country code: DE

Payment date: 20230223

Year of fee payment: 19

Ref country code: BE

Payment date: 20230227

Year of fee payment: 19

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230528